An HIV drug can bind to and alter the function of an immune molecule, causing a dangerous reaction in patients with a particular allele.
Advertisement
The Scientist
Most Recent
Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.
An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.
The FDA approves the use of Truvada for those at high risk of HIV infection.
Sensitive tests reveal the Berlin patient believed to be cured of HIV still carries HIV RNA and antibodies.
New computational modeling suggests pre-existing HIV drug resistance mutations may contribute more to drug failure than previously thought.
African justice systems must change to help curb HIV and tuberculosis transmission in prisons.
Sangamo Biosciences is putting a different spin on gene therapy. Rather than replace or supplement a mutated gene with an accurate copy, Sangamo researchers are introducing a mutant copy of the gene for the HIV co-receptor CCR5 into the T cells of HI
After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.
The anti-HIV antibodies from mothers carrying HIV could be used to help develop a vaccine.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Advertisement
Current Issue
